|
|
|
|
R-026 / R-026-1ML updated item number format
Remifentanil acid
100 ug/mL in Acetonitrile | Certified Reference Material
|
|
Remifentanil acid is the major urinary metabolite of remifentanil, a synthetic opioid used to induce or supplement general anesthesia. This new certified reference solution is suitable for a variety of mass spectrometry-based testing applications including clinical toxicology, forensic analysis, workplace drug testing and pharmaceutical research.
|
|
|
|
|
| Concentration:
|
100 ug/mL
|
| Solvent:
|
Acetonitrile
|
| Unit Size:
|
1mL/ampoule
|
| CAS Number:
|
132875-68-4
|
| Chemical Formula:
|
C19H26N2O5
|
| Molecular Weight:
|
362.42
|
| Certificate of Analysis:
|
|
| US List Price:
|
|
|
|
|
| A-071 / A-071-1ML |
|
Alfentanil HCl, 1.0 mg/mL (as free base)
|
|
$95.50
|
|
|
|
|
|
| A-109 / A-109-1ML |
|
Acetyl fentanyl, 1.0 mg/mL
|
|
$108.00
|
|
|
|
|
|
| A-110 / A-110-1ML |
|
Acetyl fentanyl-13C6, 100 µg/mL
|
|
$167.00
|
|
|
|
|
|
| A-115 / A-115-1ML |
|
Acetyl norfentanyl oxalate, 1.0 mg/mL (as free base)
|
|
$131.00
|
|
|
|
|
|
| A-116 / A-116-1ML |
|
Acetyl norfentanyl-13C6 oxalate, 100 µg/mL (as free base)
|
|
$167.00
|
|
|
|
|
|
| B-066-0.5ML |
|
Butyryl fentanyl, 100 μg/mL
|
|
$112.00
|
|
|
|
|
|
| F-001 / F-001-1ML |
|
Fentanyl-D5, 100 μg/mL
|
|
$43.30
|
|
|
|
|
|
| F-002 / F-002-1ML |
|
Fentanyl, 100 μg/mL
|
|
$27.70
|
|
|
|
|
|
| F-013 / F-013-1ML |
|
Fentanyl, 1.0 mg/mL
|
|
$48.50
|
|
|
|
|
|
| N-030 / N-030-1ML |
|
Norfentanyl-D5 oxalate, 100 μg/mL (as free base)
|
|
$43.30
|
|
|
|
|
|
| N-031 / N-031-1ML |
|
Norfentanyl oxalate, 1.0 mg/mL (as free base)
|
|
$27.70
|
|
|
|
|
|
| N-055 / N-055-1ML |
|
Norfentanyl-D5 oxalate, 1.0 mg/mL (as free base)
|
|
$389.00
|
|
|
|
|
|
| P-071 / P-071-1ML |
|
Pain Management Multi-Component Opiate Mixture-13, 100 μg/mL of each component; 10 μg/mL of Fentanyl
|
|
$441.00
|
|
|
|
|
|
| S-008 / S-008-1ML |
|
Sufentanil Citrate, 100 μg/mL (as free base)
|
|
$125.00
|
|
|
|
|
|
| S-018 / S-018-1ML |
|
Sufentanil-D5, 100 μg/mL
|
|
$243.00
|
|
|
|
|
|
|
|
|